Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/068888external-prioritypatent/WO2010075239A1/en
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of CU20130155A7publicationCriticalpatent/CU20130155A7/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Los moduladores o agonistas de los receptores de S1P se administran siguiendo un régimen de dosificación en donde, durante los días iniciales del tratamiento, la dosificación diaria es más baja que la dosificación diaria convencional.The modulators or agonists of the S1P receptors are administered following a dosage regimen where, during the initial days of treatment, the daily dosage is lower than the conventional daily dosage.
CU2013000155A2009-09-292013-11-20
DOSAGE REGIME FOR A S1P RECEIVER AGONIST
CU20130155A7
(en)
Compounds derived from spiropiperidine-methylbenzyloxyphenyl, activators of the rpg-40 receptor; pharmaceutical composition comprising them; and use of the compound to treat diabetes.
Pharmaceutical combination comprising a glp-1 receptor agonist and linagliptin, dpp-4 inhibitor; use of the pharmaceutical combination for the treatment of type 2 diabetes and obesity.
Combinations of a) an adrenergic beta-3 receptor agonists and b) muscarinic receptor antagonists to treat overactive bladder; a method of treatment for the overactive bladder comprising the combination.
Use of a sphingosine-1-phosphate (s1p) agonist derived from aminopropanediol to treat cerebral malaria; Pharmaceutical formulation and pharmaceutical form comprising the s1p agonist and an antimalarial drug.
Use of dronedarone to prepare a medication for the treatment of patients with arrhythmia, patients having an increase in creatinine level due to the use of dronedarone.